| System Organ Class  Preferred Term[a] | Drug A | Active Control | Placebo |
| --- | --- | --- | --- |
| Number of patients reporting at least one treatment-emergent adverse event | 8 (80.0%) | 5 (62.5%) | 11 (78.6%) |
| Blood and lymphatic system disorders | 0 ( 0.0%) | 1 (12.5%) | 0 ( 0.0%) |
| Anaemia | 0 ( 0.0%) | 1 (12.5%) | 0 ( 0.0%) |
| Gastrointestinal disorders | 5 (50.0%) | 3 (37.5%) | 9 (64.3%) |
| Abdominal distension | 0 ( 0.0%) | 0 ( 0.0%) | 2 (14.3%) |
| Abdominal pain | 0 ( 0.0%) | 0 ( 0.0%) | 2 (14.3%) |
| Diarrhoea | 0 ( 0.0%) | 1 (12.5%) | 2 (14.3%) |
| Dyspepsia | 1 (10.0%) | 1 (12.5%) | 3 (21.4%) |
| Eructation | 0 ( 0.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Gastrooesophageal reflux disease | 1 (10.0%) | 0 ( 0.0%) | 3 (21.4%) |
| Nausea | 4 (40.0%) | 2 (25.0%) | 3 (21.4%) |
| Vomiting | 2 (20.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| General disorders and administration site conditions | 2 (20.0%) | 0 ( 0.0%) | 3 (21.4%) |
| Chills | 1 (10.0%) | 0 ( 0.0%) | 0 ( 0.0%) |
| Injection site haemorrhage | 1 (10.0%) | 0 ( 0.0%) | 2 (14.3%) |
| Peripheral swelling | 0 ( 0.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Infections and infestations | 1 (10.0%) | 0 ( 0.0%) | 0 ( 0.0%) |
| Urinary tract infection | 1 (10.0%) | 0 ( 0.0%) | 0 ( 0.0%) |
| Investigations | 0 ( 0.0%) | 1 (12.5%) | 0 ( 0.0%) |
| Coagulation test abnormal | 0 ( 0.0%) | 1 (12.5%) | 0 ( 0.0%) |
| Metabolism and nutrition disorders | 4 (40.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Decreased appetite | 1 (10.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Hypoglycaemia | 3 (30.0%) | 0 ( 0.0%) | 0 ( 0.0%) |
| Musculoskeletal and connective tissue disorders | 0 ( 0.0%) | 0 ( 0.0%) | 2 (14.3%) |
| Arthralgia | 0 ( 0.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Back pain | 0 ( 0.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Nervous system disorders | 2 (20.0%) | 2 (25.0%) | 4 (28.6%) |
| Dizziness | 0 ( 0.0%) | 0 ( 0.0%) | 2 (14.3%) |
| Headache | 2 (20.0%) | 2 (25.0%) | 3 (21.4%) |
| Renal and urinary disorders | 2 (20.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Pollakiuria | 2 (20.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Skin and subcutaneous tissue disorders | 1 (10.0%) | 1 (12.5%) | 1 ( 7.1%) |
| Dermatitis | 0 ( 0.0%) | 0 ( 0.0%) | 1 ( 7.1%) |
| Rash | 0 ( 0.0%) | 1 (12.5%) | 0 ( 0.0%) |
| Skin hyperpigmentation | 1 (10.0%) | 0 ( 0.0%) | 0 ( 0.0%) |